347.34MMarket Cap-8182P/E (TTM)
13.630High11.770Low98.31KVolume11.990Open11.760Pre Close1.26MTurnover1.06%Turnover RatioLossP/E (Static)26.88MShares24.00052wk High1.80P/B119.46MFloat Cap11.68052wk Low--Dividend TTM9.25MShs Float24.000Historical High--Div YieldTTM15.82%Amplitude11.680Historical Low12.766Avg Price1Lot Size
Alto Neuroscience Stock Forum
NEWS
Alto Neuroscience Announces Positive Phase 1 Results for ALTO-101, a Novel PDE4 Inhibitor in Development for Schizophrenia
ALTO-101 demonstrated favorable pharmacokinetic and tolerability profile in Phase 1 study
Transdermal formulation provided significantly greater drug exposure with fewer adverse events
Proof-of-concept study for CIAS to start in the first half of 2024
Topline data expected in the second half of 2025
Achievement of target exposure with propri...
No comment yet